JP7409612B2 - トリパタイトモチーフ含有蛋白質16(trim16)シグナル伝達を誘導するための組成物及び方法 - Google Patents

トリパタイトモチーフ含有蛋白質16(trim16)シグナル伝達を誘導するための組成物及び方法 Download PDF

Info

Publication number
JP7409612B2
JP7409612B2 JP2020541958A JP2020541958A JP7409612B2 JP 7409612 B2 JP7409612 B2 JP 7409612B2 JP 2020541958 A JP2020541958 A JP 2020541958A JP 2020541958 A JP2020541958 A JP 2020541958A JP 7409612 B2 JP7409612 B2 JP 7409612B2
Authority
JP
Japan
Prior art keywords
cancer
pamp
rig
trim16
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020541958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512123A (ja
JP2021512123A5 (cg-RX-API-DMAC7.html
Inventor
マイケル, ジェー., ジュニア ゲイル,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Original Assignee
WASHINGTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WASHINGTON, University of filed Critical WASHINGTON, University of
Publication of JP2021512123A publication Critical patent/JP2021512123A/ja
Publication of JP2021512123A5 publication Critical patent/JP2021512123A5/ja
Application granted granted Critical
Publication of JP7409612B2 publication Critical patent/JP7409612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020541958A 2018-02-02 2019-02-01 トリパタイトモチーフ含有蛋白質16(trim16)シグナル伝達を誘導するための組成物及び方法 Active JP7409612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625623P 2018-02-02 2018-02-02
US62/625,623 2018-02-02
PCT/US2019/016413 WO2019152884A1 (en) 2018-02-02 2019-02-01 Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Publications (3)

Publication Number Publication Date
JP2021512123A JP2021512123A (ja) 2021-05-13
JP2021512123A5 JP2021512123A5 (cg-RX-API-DMAC7.html) 2022-02-03
JP7409612B2 true JP7409612B2 (ja) 2024-01-09

Family

ID=67479930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541958A Active JP7409612B2 (ja) 2018-02-02 2019-02-01 トリパタイトモチーフ含有蛋白質16(trim16)シグナル伝達を誘導するための組成物及び方法

Country Status (9)

Country Link
US (1) US20210046168A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746088B1 (cg-RX-API-DMAC7.html)
JP (1) JP7409612B2 (cg-RX-API-DMAC7.html)
KR (1) KR102828978B1 (cg-RX-API-DMAC7.html)
CN (1) CN111836623A (cg-RX-API-DMAC7.html)
AU (1) AU2019215191B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015821A2 (cg-RX-API-DMAC7.html)
RU (1) RU2020128838A (cg-RX-API-DMAC7.html)
WO (1) WO2019152884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2022550454A (ja) * 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン B型肝炎ウイルス感染の治療のための組成物及び方法
EP4058581A1 (en) * 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
EP4112665A4 (en) * 2020-03-27 2024-04-10 Mitsui Chemicals, Inc. LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン 5’リン酸オリゴヌクレオチドの構造および使用
US20150017207A1 (en) 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003218181A1 (en) 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US10624964B2 (en) * 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
CN117244049A (zh) * 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン 5’リン酸オリゴヌクレオチドの構造および使用
US20150017207A1 (en) 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Advances in Immunology,2017年,Vol. 133,pp. 121-169
DEWEY, Elyse C. et al.,Programming of RIG-I signaling through co-factor interactions,J Immunol,2016年,196 (1 Supplement) 203.7
Molecular & Cellular Oncology,2014年,Vol. 1, No. 4,e968016, pp. 1-6
PLOS Pathogens,2012年,Vol. 8, No. 8,e1002839, pp. 1-13

Also Published As

Publication number Publication date
EP3746088B1 (en) 2024-07-10
KR20200116976A (ko) 2020-10-13
KR102828978B1 (ko) 2025-07-02
WO2019152884A1 (en) 2019-08-08
EP3746088A1 (en) 2020-12-09
EP3746088C0 (en) 2024-07-10
JP2021512123A (ja) 2021-05-13
US20210046168A1 (en) 2021-02-18
EP3746088A4 (en) 2023-02-22
AU2019215191B2 (en) 2025-08-14
AU2019215191A1 (en) 2020-09-17
CN111836623A (zh) 2020-10-27
RU2020128838A (ru) 2022-03-03
BR112020015821A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
EP3746088B1 (en) Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
Wang et al. The BET family in immunity and disease
Bavelloni et al. AKT‐dependent phosphorylation of the adenosine deaminases ADAR‐1 and‐2 inhibits deaminase activity
CN110420331B (zh) Alkbh5抑制物在治疗病毒感染性疾病中的应用
JP2022534138A (ja) Altがんの処置
CN110393791A (zh) hnRNPA2B1的抗感染作用及其应用
US8021879B2 (en) Adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof
CN112996802B (zh) 用于制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
CN109609644B (zh) Pax3-fkhr和acta1基因在预防、治疗横纹肌肉瘤中的用途
US20060052322A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US9296994B2 (en) Archease as RNA ligaes complex member
CN107502610A (zh) 一种靶向STAT3信号通路miRNA及其制备方法和应用
KR102395241B1 (ko) Pcaf 매개 uhrf1 아세틸화 조절을 통한 dna 메틸화 조절 용도
JP2022529562A (ja) オリゴヌクレオチド分子及び腫瘍治療におけるその応用
AU2002346223B2 (en) Medicinal compositions
JP2005312304A (ja) 新規インターフェロン制御因子活性化ポリペプチド及びそれをコードする核酸
WO2023077133A2 (en) Controlling homeostatic regulatory circuitry in hypothalamus
Xu et al. Construction of a recombinant pIRES2-EGFP-ARTS plasmid and its effect on LX-2 cells
CN106319020B (zh) p97基因治疗病毒感染的用途及其相关药物
JP2018070563A (ja) 抗癌作用増強剤及び癌治療支援方法
HK40122461A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
JP2003221349A (ja) p73のアポトーシス誘導調節剤
KR20150130669A (ko) Abi1 발현 또는 활성 억제제를 포함하는 C형 간염 예방 및 치료용 약제학적 조성물
WO2021034634A2 (en) Compositions and methods utilizing a novel human foxo3 isoform
WO2020075836A1 (ja) B型肝炎ウイルス複製阻害剤及びそれを含むb型肝炎治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231213

R150 Certificate of patent or registration of utility model

Ref document number: 7409612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150